Inspira Technologies has announced the development of a new augmented respiration technology, dubbed the VORTX Blood Oxygenator, to imitate lung function.

The technology will mainly focus on efficiently saturating the blood with oxygen and eliminating carbon dioxide.

VORTX, which is currently under development, is anticipated to enhance haemodynamic performance and minimise oxygenator failure.

According to the company, the existing blood oxygenator market relies on hollow fibre membrane technology, which has been linked to medical complications including device failure, coagulation and haemolysis.

These issues pose risks and have an impact on patient outcomes.

Inspira is developing a new blood oxygenator to function as an independent stand-alone disposable unit.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will also be compatible with the company’s INSPIRAART (augmented respiration technology) system and ALICEdevice.

INSPIRAART system has been developed to rebalance the oxygen saturation levels of patients.

Once the development and testing of VORTX are completed, the unit is anticipated to be submitted to the US Food and Drug Administration (FDA) for regulatory review and subsequent approval.

Inspira Technologies chief technology officer Dr Daniella Yeheskely-Hayon said: “Having vast experience in blood oxygenation development, my team and I are excited to lead the development of the revolutionary VORTXBlood Oxygenator.

“Inspira Technologies’ highly advanced testing laboratories are core to the development of this new technological approach.”